Basic Information
| LncRNA/CircRNA Name | CRART16 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qRT-PCR, Microarray |
| Sample | CRC cell lines(HCT116, HT29, HCT8,SW620 and Caco-2) |
| Expression Pattern | up-regulated |
| Function Description | CRART16 overexpression reversed the effects of cetuximab on cell viability and reduced cetuximab-induced apoptosis.CRART16 overexpression led to increases in the proportion of CD44 + /CD133 + cells.CRART16 acts as a competing endogenous RNA (ceRNA) for miR-371a-5p to regulate V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 3 (ERBB3) expression. |
| Pubmed ID | 32158358 |
| Year | 2020 |
| Title | The novel long noncoding RNA CRART16 confers cetuximab resistance in?colorectal cancer cells by enhancing ERBB3 expression via?miR-371a-5p |
External Links
| Links for CRART16 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |